Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Recurso digital |
| Language: | English |
| Published: |
Zenodo
2026
|
| Subjects: | |
| Online Access: | https://doi.org/10.5281/zenodo.18630367 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- <p>"Obesity and Type 2 Diabetes (T2D) are major public health issues, associated with several comorbidities and increased mortality worldwide. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has emerged as the most prevalent form of chronic liver disease closely related to both obesity and T2D. The ketogenic diet, referred to as a Very Low Energy Ketogenic Therapy (VLEKT), is increasingly applied in clinical setting for its effectiveness in promoting weight loss. It has also shown promise in reducing hepatic<br>fat accumulation and fibrosis. However, the effects of VLEKT on glucometabolic parameters<br>remained to be fully clarified. Aim: This 12-weeks pilot study aimed to evaluate the efficacy of the VLEKT on body composition, glucometabolic and liver parameters in obese subjects diagnosed with T2D and MASLD."</p>